Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05607303 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Hormones on Frequency of Headache and Brain Structure and Function in Puberty

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Jun 30, 2026 to Jun 30, 2027 Enrollment target: estimated 140 to confirmed 138 · Eligibility criteria expanded, about 9 words · Site details revised Show 3 more changesShow less
    • Enrollment target: estimated 140 to confirmed 138
    • Eligibility criteria expanded, about 9 words
    • Site details revised
  2. Primary completion date: Jun 2025 to Jun 30, 2026 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 2025 to Jun 30, 2026 · Site details revisedv6 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 2025 to Jun 30, 2026
    • Site details revised
  3. Completion date: Jun 2025 to Dec 2025 Site contact updatedv5 Show 1 more changeShow less
    • Site contact updated
  4. Re-verified, no change to tracked fieldsv4
  5. Site contact updatedv3
  6. Primary and study completion dates: Dec 2023 to Jun 2025 Eligibility criteria revised · Site contact updatedv2 Show 2 more changesShow less
    • Eligibility criteria revised
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
With a rising population of transgender adults and youth, there is a need for more research to meet the needs of this community. Transfemale (MTF) youth (male sex, female gender identity) who begin clinical Gender Affirming Hormone Therapy (GAHT) with estrogen may be at a higher risk for headache since estrogen has been linked to headache in cisgender females (female sex, female gender identity). This research hopes to learn more about headache in MTF youth.
Trial Details
NCT Number NCT05607303
Lead Sponsor University of Colorado, Denver
Conditions Headache, Gender Identity
Enrollment 138 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov